Nonetheless, such association is strongly supported by increase of GLIS2 expression in tumors with T cell dysfunction among 4 of 5 cancer populations (Fig. 8a, top panel), its association with poor prognosis in melanoma, bladder cancer, and ccRCC treated with ICB (Fig. 8a, middle panel), as well as its upregulation in stromal cells with demonstrated roles in immune evasion: CAF (cancer-associated fibroblasts) and MDSC (myeloid-derived suppressor cells) (Fig. 8a, bottom panel). Here, GLIS2 is linked to melanoma.